- Home
- ABBV
ABBV
AbbVie Inc.
as 12-20-2024 4:00pm EST
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NORTH CHICAGO |
| Market Cap: | 303.1B | IPO Year: | N/A |
| Target Price: | $207.45 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 22 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 2.87 | EPS Growth: | -21.44 |
| 52 Week Low/High: | $153.09 - $207.32 | Next Earning Date: | 01-31-2025 |
| Revenue: | $55,533,000,000 | Revenue Growth: | 0.72% |
| Revenue Growth (this year): | 5.28% | Revenue Growth (next year): | 5.73% |
Stock Insider Trading Activity of AbbVie Inc. (ABBV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buckbee Kevin K | ABBV | SVP, CONTROLLER | Dec 16 '24 | Sell | $172.24 | 1,800 | $310,032.00 | 6,983 |
Latest AbbVie Inc. News
ABBV Breaking Stock News: Dive into ABBV Ticker-Specific Updates for Smart Investing
Motley Fool
6 hours ago
3 Fantastic Stocks That Could Enjoy a Santa Claus Rally
Zacks
a day ago
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
CNW Group
2 days ago
AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline
Motley Fool
2 days ago
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
Insider Monkey
2 days ago
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?
Zacks
3 days ago
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Clinical Trials Arena
3 days ago
AbbVie’s tavapadon achieves positive topline results in Phase III TEMPO-2 trial
Zacks
3 days ago
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Compare ABBV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ABBV AbbVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.